SCHEMBL178382

SCHEMBL178382

O=C1CC(CNc2ccc3ncc(-c4cccc(O)c4)n3n2)CCN1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 15/20 0.74
PIM2 Q9P1W9 2/20 0.58
FYN P06241 5/20 0.57
MKNK1 Q9BUB5 1/20 0.54
KCNH2 Q12809 2/20 0.51
GAK O14976 1/20 0.50
STK10 O94804 1/20 0.50
YES1 P07947 1/20 0.50
RET P07949 1/20 0.50
PDGFRB P09619 1/20 0.50
CSNK2A2 P19784 1/20 0.50
FLT3 P36888 1/20 0.50
ACVR1 Q04771 1/20 0.50
PKN1 Q16512 1/20 0.50
PIM3 Q86V86 1/20 0.50
HASPIN Q8TF76 1/20 0.50
SIK2 Q9H0K1 1/20 0.50
SLK Q9H2G2 1/20 0.50
BMP2K Q9NSY1 1/20 0.50
PRKAG2 Q9UGJ0 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL178348 0.86 PIM1 (0.72) PIM1PIM2FYNMKNK1KCNH2
SCHEMBL2948202 0.86 FYN (0.74) PIM1PIM2FYNMKNK1KCNH2
SCHEMBL102153 0.85 PIM1 (1.00) PIM1PIM2FYNKCNH2GAK
SCHEMBL2950822 0.75 PIM1 (0.83) PIM1PIM2FYNKCNH2
SCHEMBL178349 0.74 PIM1 (0.77) PIM1PIM2FYNKCNH2GAK
SCHEMBL2945011 0.74 FYN (0.71) PIM1PIM2FYNKCNH2GAK
SCHEMBL2950857 0.74 PIM1 (1.00) PIM1PIM2FYNKCNH2GAK
SCHEMBL2943175 0.74 PIM1 (0.81) PIM1PIM2FYNKCNH2
SCHEMBL2949038 0.73 FYN (1.00) PIM1FYNMKNK1HASPIN
SCHEMBL30521854 0.73 FYN (1.00) PIM1FYNMKNK1HASPIN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058997-A1 IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058997-A1 IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885FYN 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.